The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | The definitive guide to multiple myeloma at ASH 2018: part I
Trialling concepts: a holistic review of MM clinical trials at ASH 2018
Multiple myeloma (MM) abstracts accounted for over a quarter of the total abstracts from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Mohamad Mohty, MD, PhD, from the University Pierre & Marie Curie, Paris, France is joined by Saad Usmani, MD, FACP, of the University of North Carolina School of Medicine, Chapel Hill, NC, to review the key data and news from the ASH 2018 meeting. Discussing the latest trial data, including updates form POLLUX (NCT02076009), CASTOR (NCT02136134), ALCYONE (NCT02195479) and the MAIA trial (NCT02252172). Exploring novel combinations, these trials have the potential to influence MM practices, Dr Mohty and Dr Usmani share their insights on how to consider and possibly incorporate these updates into their own clinical practice.
